dupilumab治疗特应性皮炎:三级转诊中心真实世界经验
结果显示EASI评分平均下降19.6分(72.4%)和22.6分(76.7%),EASI、DLQI、瘙痒评分、睡眠评分、IgE和LDH均显著降低,3个月时EASI与LDH下降显著相关(P=0.003)。1例(2.3%)因副作用停药,7例(18.4%)发生结膜炎。
要点
- dupilumab在真实世界中1个月和3个月EASI分别改善72.4%和76.7%。
- DLQI、瘙痒、睡眠、IgE和LDH在1个月和3个月均显著下降。
- 3个月EASI与LDH下降显著相关(P=0.003),LDH或可预测疗效。
核心结论
- 真实世界中dupilumab治疗特应性皮炎的疗效和安全性可与3期临床试验相比。
- LDH被建议作为预测治疗反应的潜在血清学标志物。
研究设计与样本
- 患者在治疗开始时及首次注射后1个月和3个月共评估三次。
主要发现
- EASI评分从基线平均下降19.6分(72.4%)在1个月随访时,下降22.6分(76.7%)在3个月随访时。
- EASI、DLQI、瘙痒评分、睡眠评分、IgE和LDH在基线至1个月和3个月随访间均呈统计学显著下降。
- 3个月随访时EASI评分与LDH的平均下降显著相关(P=0.003)。
- 1例患者(2.3%)因副作用停止治疗,7例患者(18.4%)在研究期间发生结膜炎。
临床怎么用
- 在真实临床实践中,dupilumab可用于中重度特应性皮炎,1个月和3个月随访可见疾病活动度和患者报告结局显著改善。
- 治疗期间需监测结膜炎等不良反应,本研究中结膜炎发生率为18.4%。
- LDH下降与EASI改善相关,可考虑作为疗效监测的潜在血清学指标。
局限性
- 研究为单中心真实世界研究,样本量43例,随访时间仅3个月。
- 原文未设对照组,无法直接比较其他系统治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of moderate-to-severe atopic dermatitis (AD) frequently requires treatment with systemic therapies. Dupilumab is the first biological agent approved for treatment of moderate-to-severe AD. Although promising results have appeared in clinical trials, real-life data on efficacy and safety are lacking. OBJECTIVES: To assess effectiveness and safety of treatment with dupilumab in the real-life clinical setting at a Danish tertiary referral centre. METHODS: All patients with AD treated with dupilumab from October 2017 to October 2018 at Bispebjerg Hospital, Denmark, were included in the study. Patients were evaluated three times: at treatment initiation and at 1 and 3 months after first dupilumab injection. At each visit, disease activity was assessed by severity score (Eczema Area and Severity Index, EASI), patient-reported outcomes (Dermatology Life Quality Index, DLQI, pruritus and sleep score) and serological markers [immunoglobulin (Ig)E, eosinophil count and lactate dehydrogenase (LDH)]. RESULTS: A total of 43 patients were included in the study. The mean reduction in EASI score from baseline was 19.6 points (72.4%) at 1-month and 22.6 points (76.7%) at 3-month follow-up. EASI, DLQI, pruritus score, sleep score, IgE and LDH were all statistically significantly reduced between baseline and 1- and 3-month follow-up. Mean reductions in EASI score and LDH at 3-month follow-up were significantly correlated (P = 0.003). One patient (2.3%) discontinued treatment due to side-effects, and seven patients (18.4%) developed conjunctivitis during the study period. CONCLUSION: The effectiveness and safety of dupilumab treatment in a real-life clinical setting are comparable to that of phase 3 clinical trials. LDH is suggested as a potential serological marker predictive of treatment response.
引用
- Olesen CM, Holm JG, Nørreslet LB, et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019. PMID: 30959559. doi:10.1111/jdv.15609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。